Bafna Pharmaceuticals share price today

Bafna Pharmaceuticals Ltd's share price was ₹438.80 at the close on 4 November 2026. It has been rising for 25 weeks. That is 79.4% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Bafna Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 29 May 2026, it has traded between ₹132 and ₹461, and at that close it sat 93% of the way up from that low.

Over the last 5 months the share price moved +233% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: profit fell in the June 2026 quarter, revenue fell in the June 2026 quarter and lowest operating margin in 10 quarters.

1. Profit fell in the June 2026 quarter

   Profit was ₹0 crore, -97.6% on a year earlier (₹3 crore), after 4 quarters of growth.

2. Revenue fell in the June 2026 quarter

   Revenue was ₹27 crore, -23.2% on a year earlier (₹35 crore), after 2 quarters of growth.

3. Lowest operating margin in 10 quarters

   Operating margin was 3.4% in the June 2026 quarter, against 14.6% a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Bafna Pharmaceuticals reported revenue of ₹26.6 crore, down 23.2% from ₹34.6 crore a year earlier, and a profit of ₹0.08 crore, down 97.6% from ₹3.39 crore.

Bafna Pharmaceuticals results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Bafna Pharmaceuticals closed at ₹438.80 on 4 November 2026. Its highest weekly close since May 2026 was ₹461.35 on 16 October 2026.

Bafna Pharmaceuticals share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

25 weekly closes from 29 May 2026 to 4 November 2026.

4 Nov 2026: Bafna Pharmaceuticals closed at ₹438.80, down 2.0% on the week and up 15.9% on the month. Results for April to June 2026: Revenue down 23.2% and profit down 97.6% on a year earlier.

Bafna Pharmaceuticals has paid no dividend on the NSE since its first NSE close in our records (29 May 2026), the start of the period we checked.

Not in its latest year. Bafna Pharmaceuticals Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 15 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

Bafna Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks.

Bafna Pharmaceuticals Ltd earned ₹0.1 Cr of net profit in the Jun 2026 quarter, −97.6% on the same quarter a year earlier. Full-year FY26 profit was ₹11.0 Cr. That is 0.3% of the quarter's revenue. The same quarter a year earlier earned ₹3.4 Cr. 2 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹11.0 Cr (+175.0% on the year before).

Why profit moved: revenue changed −23.2% on a year earlier and the margin moved −11.3 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +31.3% and revenue −2.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Bafna Pharmaceuticals Ltd reported ₹26.6 Cr of revenue in the Jun 2026 quarter, −23.2% on the same quarter a year earlier. Over 10 years it has grown 5.9% a year on average. The last full year, FY26, came in at ₹151 Cr. The last four reported quarters add to ₹143 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹151 Cr, +3.4% on the year before.

Recent pace: the last four quarters grew −2.9% on average, against 5.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −3.1%, against −0.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −5.8%, against +427.5% a year (rolling over).

Bafna Pharmaceuticals Ltd's operating margin was 3.4% in the Jun 2026 quarter, 11.3 percentage points lower than the same quarter a year ago. Across 15 years it has been between −77.0% and 15.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −11.3 percentage points on the year while gross margin changed +2.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 209% of Bafna Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹15.0 Cr of operating cash against ₹11.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹25.0 Cr of spending on assets, free cash was −₹10.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 209% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 3.7× depreciation over three years. The next section checks what that spending is building.

Bafna Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 96 days in FY26, down from 96 days in FY21. It spent ₹59.0 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 129 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹151 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹40.0 Cr is tied up in the business at any time.

FY26: customers took 106 days to pay and stock sat for 129 days, about 4.2 months of sales sitting as stock, for a full cycle of 96 days, shorter than FY21's 96.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 129 days. Customers pay about 106 days after that. Suppliers are paid at 139 days. Together that makes the 96-day cycle.

Spending on assets: ₹59.0 Cr over the last 3 years, against ₹16.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Bafna Pharmaceuticals Ltd's P/E is 133.2×, near the high end of its own history: higher than 87% of past readings. Its usual P/E (the middle reading) is 40.5×, over 8.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Bafna Pharmaceuticals Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 10.3%; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Bafna Pharmaceuticals Ltd earned a ROCE of 12% in FY26. That is up from a low of −35% in FY18. Its return on capital used (ROIC) is 8.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 7.3% net margin and 0.86× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 7.3% net margin × 0.86× asset turnover × 1.83× leverage (assets divided by equity) ≈ 11.5% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 4.0% − 12.0% = −8.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 4.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 8.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Bafna Pharmaceuticals Ltd has total debt of ₹37.0 Cr against shareholder equity of ₹96.0 Cr as of Jun 2026, so its debt is 0.39× its equity. Year by year, that ratio went from 0.18 in FY22 to 0.39 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Promoters cut their stake in Bafna Pharmaceuticals Ltd by 13.3 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 75.0% of the company. Foreign institutions moved +9.3 points over the same period, to 9.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why the owners changed: promoters drove it (−13.3 points), with the other side taken by foreign institutions (+9.3 points). They reduced their stake.

For Bafna Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

35.8 out of 100, rank 36 of 44 in Pharma - Formulators, with 74% of the evidence available.

Bafna Pharmaceuticals Ltd scores 35.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 36. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 7.1 + 5.4 + 10.8 + 12.5 = 35.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Bafna Pharmaceuticals ranks 36 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 35.8 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Formulators, all 44 compared on one page.

Bafna Pharmaceuticals is the 38th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Accent Microcell, Amrutanjan Health Care and Bharat Parenterals. Just below it: Bajaj Healthcare, Lincoln Pharmaceuticals and Zim Laboratories.

Pharma - Formulators companies close in size

35. Accent Microcell Ltd ₹1,533 crore
36. Amrutanjan Health Care Ltd ₹1,436 crore
37. Bharat Parenterals Ltd ₹1,399 crore
38. Bafna Pharmaceuticals Ltd ₹1,060 crore
39. Bajaj Healthcare Ltd ₹1,031 crore
40. Lincoln Pharmaceuticals Ltd ₹1,000 crore
41. Zim Laboratories Ltd ₹731 crore

All 44 Pharma - Formulators companies, largest first

Companies close in size in other industries

1556. Andhra Sugars Ltd ₹1,065 crore · Sugar
1557. Sula Vineyards Ltd ₹1,061 crore · Alcoholic Beverages
1558. Bafna Pharmaceuticals Ltd ₹1,060 crore
1559. Pervasive Commodities Ltd ₹1,060 crore · Trading
1560. Sahasra Electronic Solutions Ltd ₹1,057 crore · Electronics - Others

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.